Effects of vitamin B12 supplementation on neurodevelopment and growth in Nepalese Infants: A randomized controlled trial by Strand, Tor A et al.
RESEARCH ARTICLE
Effects of vitamin B12 supplementation on
neurodevelopment and growth in Nepalese
Infants: A randomized controlled trial
Tor A. StrandID
1,2*, Manjeswori Ulak2,3, Mari Hysing4, Suman Ranjitkar3,
Ingrid KvestadID
5, Merina ShresthaID
3, Per M. Ueland6, Adrian McCannID
6, Prakash
S. Shrestha3, Laxman S. ShresthaID
3, Ram K. Chandyo7
1 Innlandet Hospital Trust, Department of Research, Lillehammer, Norway, 2 Centre for International Health,
University of Bergen, Bergen, Norway, 3 Department of Pediatrics, Child Health Research Project, Institute of
Medicine, Tribhuvan University, Kathmandu, Nepal, 4 Department of Psychosocial Science, University of
Bergen, Bergen, Norway, 5 Regional Center for Child and Youth Mental Health and Child Welfare, NORCE
Norwegian Research Centre, Bergen, Norway, 6 Bevital AS, Bergen, Norway, 7 Department of Community




Vitamin B12 deficiency is common and affects cell division and differentiation, erythropoie-
sis, and the central nervous system. Several observational studies have demonstrated
associations between biomarkers of vitamin B12 status with growth, neurodevelopment, and
anemia. The objective of this study was to measure the effects of daily supplementation of
vitamin B12 for 1 year on neurodevelopment, growth, and hemoglobin concentration in
infants at risk of deficiency.
Methods and findings
This is a community-based, individually randomized, double-blind placebo-controlled trial
conducted in low- to middle-income neighborhoods in Bhaktapur, Nepal. We enrolled 600
marginally stunted, 6- to 11-month-old infants between April 2015 and February 2017. Chil-
dren were randomized in a 1:1 ratio to 2 μg of vitamin B12, corresponding to approximately 2
to 3 recommended daily allowances (RDAs) or a placebo daily for 12 months. Both groups
were also given 15 other vitamins and minerals at around 1 RDA. The primary outcomes
were neurodevelopment measured by the Bayley Scales of Infant and Toddler Development
3rd ed. (Bayley-III), attained growth, and hemoglobin concentration. Secondary outcomes
included the metabolic response measured by plasma total homocysteine (tHcy) and
methylmalonic acid (MMA). A total of 16 children (2.7%) in the vitamin B12 group and 10 chil-
dren (1.7%) in the placebo group were lost to follow-up. Of note, 94% of the scheduled daily
doses of vitamin B12 or placebo were reported to have been consumed (in part or
completely). In this study, we observed that there were no effects of the intervention on the
Bayley-III scores, growth, or hemoglobin concentration. Children in both groups grew on an
average 12.5 cm (SD: 1.8), and the mean difference was 0.20 cm (95% confidence interval
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(CI): −0.23 to 0.63, P = 0.354). Furthermore, at the end of the study, the mean difference in
hemoglobin concentration was 0.02 g/dL (95% CI: −1.33 to 1.37, P = 0.978), and the differ-
ence in the cognitive scaled scores was 0.16 (95% CI: −0.54 to 0.87, P = 0.648). The tHcy
and MMA concentrations were 23% (95% CI: 17 to 30, P < 0.001) and 30% (95% CI: 15 to
46, P < 0.001) higher in the placebo group than in the vitamin B12 group, respectively. We
observed 43 adverse events in 36 children, and these events were not associated with the
intervention. In addition, 20 in the vitamin B12 group and 16 in the placebo group were hospi-
talized during the supplementation period. Important limitations of the study are that the
strict inclusion criteria could limit the external validity and that the period of vitamin B12 sup-
plementation might not have covered a critical window for infant growth or brain
development.
Conclusions
In this study, we observed that vitamin B12 supplementation in young children at risk of vita-
min B12 deficiency resulted in an improved metabolic response but did not affect neurodeve-
lopment, growth, or hemoglobin concentration. Our results do not support widespread
vitamin B12 supplementation in marginalized infants from low-income countries.
Trial registration
ClinicalTrials.gov NCT02272842
Universal Trial Number: U1111-1161-5187 (September 8, 2014)
Trial Protocol: Original trial protocol: PMID: 28431557 (reference [18]; study protocols
and plan of analysis included as Supporting information).
Author summary
Why was this study done?
• Many marginalized children fail to reach their cognitive and growth potential.
• Subclinical vitamin B12 deficiency, which is poor vitamin B12 status without overt clinical
symptoms, is common in this population in Nepal.
• Vitamin B12 deficiency in children is associated with anemia (low hemoglobin concentra-
tion), stunted growth, and poor neurodevelopment.
What did the researchers do and find?
• In this population-based, double-blind, randomized controlled trial (RCT), we measured the
effects of daily supplementation of vitamin B12 for 1 year in 600 infants.
• The primary outcomes were neurodevelopment, growth, and hemoglobin concentration.
• We targeted stunted infants as these children are at risk of vitamin B12 deficiency.
• Daily supplementation of vitamin B12 for a year resulted in a metabolic profile reflecting sub-
stantially improved B12 status (lower total homocysteine (tHcy) and methylmalonic acid
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(MMA) concentrations) but did not affect neurodevelopment, growth, or hemoglobin
concentration.
What do these findings mean?
• In spite of the improved metabolic profile following vitamin B12 supplementation, the find-
ings do not support widespread vitamin B12 supplementation to improve short-term growth,
neurodevelopment, or hemoglobin concentration in infants.
Introduction
Vitamin B12 (cobalamin) deficiency is common and affects all ages worldwide [1–3]. Animal-
based foods are the primary sources, and poor status is prevalent in South Asia as well as in
other low- and middle-income regions with low consumption of meat, animal milk, and fish
[3,4].
Vitamin B12 is required for cell division and differentiation, utilization of energy, and other
critical metabolic processes [5–7]. Failure to thrive, delayed development, and macrocytic ane-
mia are typical manifestations in children with severe deficiency [8]. Several observational
studies have demonstrated associations between biomarkers of vitamin B12 status with growth,
neurodevelopment, and anemia [1,9–14]. The results from these studies suggest that the nega-
tive consequences of poor B12 nutrition are also seen in suboptimal B12 status, and not only in
those with clinical deficiency. These observations, however, may be due to factors such as
unmeasured confounding or limitations in the biomarkers used to assess vitamin B12 status.
Three randomized controlled trials (RCTs) have measured the effect of vitamin B12 supple-
mentation on neurodevelopment in children with suboptimal B12 status. Of these, 2 facility-
based RCTs in infants born at low birth weight or who had developmental delay showed that a
high dose of vitamin B12 (400-μg hydroxycobalamin intramuscularly) substantially improved
motor development [15,16]. In the third study, a population-based RCT in young North
Indian children, there was a small borderline significant beneficial effect of daily oral supple-
mentation with 1.8 μg of vitamin B12 for 6 months on neurodevelopment [17]. The evidence
from these RCTs support the notion that poor vitamin B12 status may be a relevant public
health concern; however, the evidence is currently not strong enough to alter widespread feed-
ing recommendations. We therefore designed the current population-based RCT to measure
the effects of daily supplementation of vitamin B12 for 1 year. In this study, we ensured that the
baseline B12 status and metabolic response to the supplementation was well characterized, and
we targeted marginally stunted infants due to their associated risk of vitamin B12 deficiency,
delayed development, and stunted growth.
Participants and methods
Study design and participants
This study is reported according to the CONsolidated Standards of Reporting Trials (CON-
SORT) guidelines (S1 Checklist). The study was a community-based, double-blind placebo-
controlled trial in Nepalese infants. We hypothesized that daily administration of 2 μg vitamin
B12 for 12 months would improve neurodevelopment, growth, and hemoglobin concentration.
We conducted the study in Bhaktapur municipality and surrounding peri-urban communities
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near the capital Kathmandu. For the last 20 years, we have shown that poor vitamin B12 status
is common in both women and children in this population [4,18,19]. Bhaktapur is among the
most densely populated municipalities in Nepal. The majority of births (96%) occur at health
centers, and 1 in every second family is living in joint households and has a separate kitchen
[20]. The primary outcomes were neurodevelopment measured by the Bayley Scales of Infant
and Toddler Development 3rd ed. (Bayley-III), attained growth (cm and kg), and hemoglobin
concentration. The secondary outcome was the metabolic response measured by plasma con-
centrations of cobalamin, total homocysteine (tHcy), and methylmalonic acid (MMA).
Ethics statement
The study received ethical clearance from the Nepal Health Research Council (NHRC; #233/
2014) and from the Regional Committee for Medical and Health Research Ethics (REC;
#2014/1528) in Norway. After detailed information was provided to parents, we obtained writ-
ten informed consent or a thumbprint from those who were illiterate (in the presence of an
impartial witness).
Enrollment, randomization, and blinding
We enrolled 600 children between April 17, 2015 and February 15, 2017. Inclusion criteria
were age 6 to 11 months, length for age z-score <−1, intent to reside in the municipality and
surrounding areas for the next 12 months, and availability of informed consent from parents.
Children were excluded if they were taking (or planned to take) supplements that contained
vitamin B12, had a severe systemic illness requiring hospitalization, if they were severely mal-
nourished (weight for length z-score <−3), were severely anemic (hemoglobin concentration
<7 g/dL), or had ongoing infections that required medical treatment. In cases of severe malnu-
trition, anemia, or infections, children received treatment and were screened again for eligibil-
ity after recovery.
Field workers identified eligible children from immunization clinics or through home visits.
Infants were enrolled by a study supervisor or by a physician at the field office. We randomized
the infants in a 1:1 ratio in blocks of 8 using a computer-generated randomization list. Ran-
domization was concealed, and the study double-blinded as the participants were only linked
to the intervention through the identification (id) number printed on the supplement labels.
The list that linked this id number to the randomization code was kept with the producers of
the supplements and the scientist who generated it. None of the investigators had access to this
list until the data collection and cleaning for the primary outcomes were completed. The vita-
min B12 supplements and placebo were produced specifically for the trial and were identical in
taste and appearance. At enrollment and end of study, we measured neurodevelopment,
weight, length, and hemoglobin concentration.
Intervention and co-interventions
All children received 2 μg of vitamin B12 (cyanocobalamin), corresponding to approximately 2
to 3 recommended daily allowances (RDAs) or placebo via a daily oral supplement for 12
months. The intervention was implemented using sachets containing 20 grams of a lipid-
based paste produced by GC Rieber Compact (Gurgaon, Haryana, India; http://www.gcrieber-
compact.com/). Each sachet provided the daily dose of supplements. To ensure that the effect
of vitamin B12 was not limited by inadequate intake of other essential nutrients, both the pla-
cebo and vitamin B12 paste contained a base multi-micronutrient mixture with several other
vitamins and minerals at approximately 1 RDA. All caregivers were given dietary recommen-
dations according to national guidelines. Children who developed diarrhea during the
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intervention period received zinc and oral rehydration solution. Those with mild to moderate
anemia (hemoglobin 7 to 10 g/dL) were treated with per oral iron for at least 30 days. Children
with pneumonia, dysentery, or other illnesses were treated according to the most recent Inte-
grated Management of Childhood Illness (IMCI) guidelines [21].
During weekly visits to the homes, field workers asked the mothers about intake of the
paste during the past 7 days and recorded in detail the amount of paste given to the children
(i.e., half, one-third, three-fourths, or less). All episodes of vomiting or regurgitation after sup-
plementation of the paste were also recorded, and the total number of empty paste sachets
were counted at the weekly visits to verify the reported compliance.
Outcomes
Neurodevelopment
The Bayley-III is a comprehensive assessment tool of neurodevelopment in infants and tod-
dlers aged 1 to 42 months [22]. The Bayley-III is often regarded as the gold standard for assess-
ing neurodevelopment in this age-group and is used in research worldwide. We administered
the Bayley-III directly with the child at enrollment and end of the study at the study research
office. The Bayley-III consists of a cognitive, language (receptive and expressive), motor (fine
and gross motor), and socio-emotional scale. Three psychologists, of whom 1 had extensive
experience with the Bayley-III, were trained to perform the assessments for the study. To
ensure high-quality measurements, we performed standardization exercises in 20 children
ahead of the enrollment where the Bayley assessments were scored by 2 raters. The psycholo-
gists were required to reach an intra-class correlation coefficient (ICC) >0.90 with the expert
rater, who served as the gold standard. Of note, 7% of the sessions during the main study were
double scored by the expert rater to ensure appropriate interobserver agreement throughout
the study. The ICCs from the quality controls ranged from 0.95 to 0.99 [23]. All the Bayley-III
assessments were video-recorded for quality purposes. The Bayley-III raw scores were con-
verted into scaled and composite scores based on U.S. citizen normative data [22]. For the
analyses, we used raw, scaled, and composite scores.
Anthropometry
Weight was measured with a portable electronic scale (model 877, Seca, California, United
States of America) that measures to the nearest 0.01 kg, and length was measured with portable
length board (model 417, Seca, California, USA). We measured length and weight at the clinic
or at home during the monthly follow-up visits. All anthropometric measurements were per-
formed twice. The mean values were used in the analyses.
Laboratory procedures
Blood samples were collected from the cubital veins into polypropylene tubes containing
EDTA (Sarstedt, Germany), which were protected from direct sunlight exposure. Up to 4-mL
blood was collected at enrollment and end of study. The hemoglobin concentration was ana-
lyzed immediately following blood sampling with HemoCue (HemoCue 201, Ångelholm, Swe-
den), which was calibrated as per the guidelines defined by the manufacturer. The blood was
centrifuged at room temperature for 10 min at 2,000 to 2,500 g within 10 min after venipunc-
ture (Model R-304, Remi, Mumbai, India). Plasma and blood cells were separated, transferred
into polypropylene vials (Eppendorf, Germany), and immediately stored at<−80˚C until anal-
ysis at Bevital Laboratory (Bergen, Norway; www.bevital.no). The samples were shipped to
Norway on dry ice by World Courier. The plasma concentrations of cobalamin and folate
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were determined using microbiological assays [24,25] using a colistinsulfate-resistant strain of
Lactobacillus leichmannii or chloramphenicol-resistant strain of Lactobacillus casei, respec-
tively. The functional biomarkers plasma total tHcy and MMA are considered to be sensitive
markers of B12 deficiency [26]. Plasma tHcy and MMA were analyzed by gas chromatography-
tandem mass spectrometry (GC-MS/MS) based on methylchloroformate derivatization [27].
The within-day coefficient of variation was 4% for both cobalamin and folate and ranged from
1% to 5% for tHcy and MMA. The between-day coefficient of variation was 5% for both cobal-
amin and folate and ranged from 1% to 8% for MMA and tHcy. We also calculated a combined
indicator of cobalamin status (3cB12) based on the 3 biomarkers cobalamin, tHcy, and MMA
as suggested by Fedosov and colleagues [28]. In short, this index is the log of the cobalamin
concentration divided by the product of the log of the tHcy and MMA concentrations.
Sample size
The study had 80% power to detect a standardized effect size of 0.22 and had 90% power to
detect an effect size of 0.28. In these calculations, we assumed a loss to follow-up of 10%.
Details on the samples size calculations are also presented in the previously published protocol
paper [18].
Statistical analyses
The analyses in this study were carried out according to the predefined protocols and analysis
plans (S1–S4 Texts). Weight for age, weight for length, and length for age z-scores were calcu-
lated using the most recent WHO growth charts [29]. We defined underweight, stunting, and
wasting as z-scores below −2 [29]. We depicted the relationship between changes in vitamin
B12 status (i.e., change in the 3cB12 values from baseline to end of study) according to vitamin
B12 status (3cB12) at baseline. To do so, we performed a kernel-weighted local polynomial
regression of delta 3cB12 on baseline 3cB12 values by treatment group and depicted these
dose-response graphs of the predicted values with 95% confidence intervals (CIs). We also
compared the concentrations of cobalamin, tHcy, and MMA between the study groups in all
infants and according to 3cB12 categories (“possible deficient,” “low,” and “adequate”) at base-
line. As these variables were left-skewed, we present the geometric means and the geometric
standard deviation factors (GSDFs). We used the log-transformed values of the end-study bio-
marker concentrations when comparing the differences between the study groups. The expo-
nentials of these mean differences are presented as the geometric mean ratio (GMR) between
the study groups.
We compared the mean end-study Bayley-III scaled and composite scores between the
intervention groups. For the other outcome variables (Bayley-III raw scores, growth, and
hemoglobin concentrations), the effects of the intervention were estimated by comparing the
changes from baseline to end study between the study groups. The precision of the effect esti-
mates and corresponding P values were calculated using the Student t test assuming equal vari-
ances. We also analyzed the data by several predefined subgroups. The subgrouping variables
were stunting (defined as length for age z-scores <−2), underweight (weight for age z-scores
<−2), low vitamin B12 status (3cB12<−0.5), low birth weight (birth weight <2,500 g), anemia
(hemoglobin concentration <11.0 g/dL), and exclusive breastfeeding. For these analyses, we
used univariate and multiple generalized linear models with the Gaussian distribution family
and identity link function adjusting for a set of predefined potential confounders. The follow-
ing variables were adjusted for in all subgroup analyses: length for age z-scores, maternal and
paternal education, and age of the child at baseline. All analyses were performed using Stata
version 16 (StataCorp, College Station, Texas, USA).
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Results
From April 2015 to February 2017, we screened 733 infants and randomized 600 into the
study (Fig 1). A total of 26 infants dropped out due to refusal or migration. Two children were
unable to complete the end-study activities, leaving 572 infants with complete neurodevelop-
mental assessments. We were able to collect and analyze blood samples for biomarker assess-
ments at end study from 567 children.
Baseline features by intervention and placebo groups are presented in Table 1. One in every
five infants was born at low birth weight, and one-third were stunted (<−2 z-score length for
age) at enrollment. The baseline features were evenly distributed between the intervention
groups. The baseline status of vitamin B12 and its plasma biomarkers were also comparable
between the intervention groups (S1 Table).
Fig 1. Trial flowchart of a study measuring the effect of daily vitamin B12 supplementation in Nepalese infants.
https://doi.org/10.1371/journal.pmed.1003430.g001
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Compliance
More than 94% of the prescribed doses were reportedly taken (94.3% in the vitamin B12 group
and 94.0% in the placebo group; S2 Table). Of these, 86.3% and 84.7% of the vitamin B12 and
placebo group, respectively, consumed the entire prescribed doses.
End points
Vitamin B12 supplementation had no effect on any of the neurodevelopmental outcomes
(Table 2). For example, the cognitive composite scores were 0.73 points (95% CI: −0.55 to 2.02,
Table 1. Baseline characteristics in a study investigating the effect of daily vitamin B12 supplementation on neurodevelopment and growth in 600 Nepalese infants.
Vitamin B12 group (n = 300) Placebo group (n = 300)
n % n %
Infant characteristics
Mean age of child (months), mean ± SD 8.1 ± 1.7 8.0 ± 1.8
Male child 158 53 151 50
Have older siblings 155 52 153 51
Low birth weight (<2,500 gm)1 56 19 59 20
Hospitalization within first month of age 28 9.3 26 8.7
Demographic features
Mother’s age, mean ± SD 27.1 ± 4.7 27.5 ± 4.6
Father’s age2, mean ± SD 30.0 ± 7.1 30.6 ± 5.1
Mothers who completed secondary school or above 197 65.7 180 60
Fathers who completed secondary school or above 199 66.3 189 63
Mothers who work 117 39.0 110 36.7
Fathers who work 286 95.3 280 93.3
Socioeconomic status
Family staying in joint family 143 47.7 149 49.7
Family residing in rented house 152 50.7 139 46.3
Number of rooms in use by the household (<−2) 163 54.3 174 58
Kitchen and bedroom in the same room 148 49.3 150 50
Family having own land 138 46 144 48
Receiving remittance from abroad 30 10 27 9
Breastfeeding status
No breastfeeding at time of interview 8 2.7 6 2
Exclusive breastfeeding for 3 months or more 143 47.7 137 45.6
Nutritional status of infants
Underweight (weight for age z-score<−2) 62 20.7 50 16.6
Stunting (length for age z-score <−2) 96 32.1 98 32.7
Wasting (weight for length z-score <−2) 12 4.0 7 2.3
Hemoglobin, g/dL, mean ± SD 10.6 ± 0.96 10.6 ± 0.91
Anemia (hemoglobin <11 g/dL) 183 61 202 67.3
Nutritional status of mother
BMI of mother, mean ± SD 23.7 ± 3.5 23.7 ± 3.6
<18.5 kg/m2 BMI of mother 15 5 19 6.3
1Among 579 infants whose birth weights were recorded.
2Among 487 fathers who were available.
n, number.
https://doi.org/10.1371/journal.pmed.1003430.t001
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P = 0.261) lower in the vitamin B12 group compared to the placebo group. There was also no effect
on growth or hemoglobin concentration (Table 3). Children in both groups grew on an average
12.5 cm (SD: 1.8), and the mean difference was 0.20 cm (95% CI: −0.23 to 0.63, P = 0.354). The
mean difference in hemoglobin concentration between the groups was 0.02 g/dL (95% CI: −1.33
to 1.37, P = 0.978). The adjusted effects of the interventions on growth and neurodevelopment by
Table 2. Effect of daily vitamin B12 supplementation for 1 year starting in infancy on the Bayley Scales of Infant Development scores among infants in Bhaktapur,
Nepal.
Bayley-III subscales Vitamin B12 group (n = 283) Placebo group (n = 289) Mean differences
Mean ± SD Mean ± SD (95% CI) (P value)
Change in raw scores from baseline until end study
Cognitive 20.9 ± 4.3 20.7 ± 4.2 0.16 (−0.54 to 0.87) (0.648)
Language
Expressive 14.4 ± 4.7 14.8 ± 5.0 0.35 (−0.44 to 1.14) (0.387)
Receptive 10.9 ± 4.0 11.2 ± 3.6 −0.31 (−0.94 to 0.32) (0.334)
Motor
Fine motor 13.8 ± 3.3 13.7 ± 2.9 0.10 (−0.41 to 0.60) (0.712)
Gross motor 21.4 ± 5.1 21.7 ± 4.7 −0.28 (−1.08 to 0.52) (0.491)
Socio-emotional 29.4 ± 14.3 31.0 ± 12.0 −1.57 (−3.96 to 0.82) (0.197)
End-study composite and scaled score
Cognitive composite score 90.5 ± 8.2 91.2 ± 7.3 0.73 (−0.55 to 2.02) (0.261)
Language composite score 93.0 ± 12.8 92.6 ± 12.6 −0.42 (−2.51 to 1.66) (0.692)
Expressive scaled score 8.6 ± 2.6 8.5 ± 2.4 −0.01 (−0.43 to 0.41) (0.965)
Receptive scaled score 9.0 ± 2.3 8.9 ± 2.5 −0.13 (−0.53 to 0.27) (0.517)
Motor composite score 99.9 ± 8.7 100.2 ± 8.3 0.32 (−1.08 to 1.73) (0.652)
Fine motor scaled score 10.7 ± 1.6 10.9 ± 1.8 0.22 (−0.06 to 0.50) (0.131)
Gross motor scaled score 9.2 ± 2.0 9.1 ± 1.7 −0.12 (−0.42 to 0.19) (0.457)
Socio-emotional composite score 104.3 ± 16.7 103.4 ± 17.1 −0.92 (−3.70 to 1.86) (0.518)
The mean differences, the corresponding 95% CI, and P values were calculated using Student t test assuming equal variances.
Bayley-III, Bayley Scales of Infant and Toddler Development 3rd ed.; CI, 95% confidence interval; n, number.
https://doi.org/10.1371/journal.pmed.1003430.t002
Table 3. Effect of vitamin B12 supplementation on growth and hemoglobin concentrations among infants in Bhaktapur, Nepal.
Vitamin B12 group (n = 283) Placebo group (n = 290) Mean differences
Mean ± SD Mean ± SD (95% CI) (P value)
Change from baseline
Length (cm) 12.5 ± 1.8 12.5 ± 1.8 0.09 (−0.21 to 0.39) (0.574)
Weight (kg) 2.1 ± 0.5 2.1 ± 0.6 −0.01 (−0.10 to 0.09) (0.919)
Hemoglobin (g/dL) 1.0 ± 1.1 1.0 ± 1.2 −0.02 (−0.20 to 0.17) (0.876)
End study
Length (cm) 78.2 ± 2.6 78.4 ± 2.6 0.20 (−0.23 to 0.63) (0.354)
Weight (kg) 9.4 ± 0.9 9.4 ± 1.0 −0.02 (−0.18 to 0.13) (0.780)
Length for age z-score −1.8 ± 0.7 −1.7 ± 0.7 0.05 (−0.06 to 0.16) (0.411)
Weight for height z-score −0.7 ± 0.8 −0.8 ± 0.8 −0.08 (−0.22 to 0.05) (0.238)
Weight for length z-score −1.4 ± 0.7 −1.4 ± 0.8 −0.04 (−0.16 to 0.08) (0.529)
Hemoglobin (g/dL) 11.6 ± 0.8 11.6 ± 1.0 0.02 (−1.33 to 1.37) (0.978)
The mean differences, the corresponding 95% CI, and P values were calculated using Student t test assuming equal variances.
CI, 95% confidence interval
https://doi.org/10.1371/journal.pmed.1003430.t003
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various subgroups are shown in S1 and S2 Figs. These analyses did not reveal any variable that
modified the effect on any of the outcomes. Unadjusted subgroup analyses yielded the same
results. We found no adverse effects of vitamin B12 supplementation (S3 Table).
The effect of vitamin B12 supplementation on B12 status expressed by the 3cB12 according
to baseline status is depicted in Fig 2. The distance between the solid and dotted lines repre-
sents the metabolic effect of the intervention, which decreased as the baseline vitamin B12 sta-
tus improved. A similar trend is displayed in S1 Table where the effects on the different
biomarkers are shown. For the functional biomarkers, tHcy and MMA, poorer vitamin B12 sta-
tus at baseline was associated with a larger effect of vitamin B12 supplementation. For example,
when restricting the analyses to infants who were classified as possibly deficient, the placebo
group had 60% higher MMA concentrations (indicating poorer vitamin B12 status) at end
study compared to those in the vitamin B12 group (GMR 1.60, 95% CI: 1.20 to 2.14,
P< 0.001). In the children who had adequate status at baseline, there was no effect of vitamin
B12 supplementation on the MMA concentration (S1 Table).
Discussion
In this year-long, double-blind, placebo-controlled RCT, daily intake of a supplement containing
vitamin B12 improved vitamin B12 status in marginally stunted Nepalese infants. Those with
poor status at the onset of the study benefitted more than those with adequate status. The inter-
vention, however, did not result in any improvements in neurodevelopment, nor was there any
effects on growth or hemoglobin concentration. Restricting the analyses to those with poor status
at baseline, i.e., those who also had the best metabolic response, did not alter these results.
Fig 2. The association between vitamin B12 status at baseline and change in vitamin B12 status from baseline to
end study by randomized group. The y-axis is the change in 3cB12 from baseline to end study, and the x-axis is the
baseline 3cB12 value. The regression lines were generated by a kernel-weighted local polynomial regression with the
change in 3cB12 as the dependent variable and 3cB12 at baseline as the independent variable. The shaded areas
represent the 95% CI of the regression lines. The profiles were generated separately for the 2 intervention groups, and
the distance between the 2 regression lines represents the effect of the vitamin B12 supplementation. The 3cB12 is a
function of the plasma concentrations of cobalamin, tHcy, and MMA. CI, 95% confidence interval; MMA,
methylmalonic acid; tHcy, total Homocysteine.
https://doi.org/10.1371/journal.pmed.1003430.g002
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Our findings are in contrast to results from the observational studies where vitamin B12 sta-
tus was positively associated with neurodevelopment, growth, and hemoglobin concentration
[10,14,30]. The findings are also at odds with results from the 3 small (group sizes of 32 to 104)
RCTs in infants and young children where vitamin B12 supplementation resulted in improved
developmental scores [15–17].
Several elements of our study design and conduct support the veracity of our findings. The
trial enrolled 600 children, of whom >95% could be included in the analyses. As a result, we
have precise effect estimates of our primary outcomes, and thus, sufficient power to detect
clinically meaningful differences between the treatment groups. The randomization was suc-
cessful as indicated by no differences in baseline characteristics, and few participants were lost
to follow-up. Finally, the compliance with supplement use was high, as it was given on nearly
95% of the scheduled days and resulted in an excellent metabolic response (S2 Table).
The study team has extensive experience with the Bayley-III, and the inter-rater reliability
was excellent during both the initial standardization exercises as well as for the quality controls
throughout the study. The Bayley-III scores were associated with established risk factors for
poor neurodevelopment [23], which provided support for the validity of the test in this study
setting. In addition, the study staff were trained and standardized for 2 decades in measuring
infant growth, ensuring precise measurements for these outcomes. Lastly, we had an effective
cold chain and used state-of-the-art biochemical methods to estimate the biomarker concen-
trations ensuring optimal description of the vitamin status.
The participants were moderately stunted infants and accordingly at risk of poor neurode-
velopment and vitamin B12 deficiency. Thus, they constituted a group of children where we
could expect an effect of vitamin B12 supplementation if subclinical deficiency affected any of
our outcomes. For practical and ethical reasons, we could not target children with defined or
overt B12 deficiency. We did not have the necessary diagnostic recourses to measure vitamin
B12 status before randomization, and giving a placebo to infants with diagnosed vitamin B12
deficiency for a year would violate the principle of clinical equipoise. Thus, the study included
some children with adequate vitamin B12 status at baseline. It is plausible that inclusion of vita-
min B12 replete children could attenuate a potential effect of the intervention. However, this
does not explain our null findings as the effect estimates did not change when we restricted the
analyses to those with evidence of deficiency.
A higher dose or a different, more effective, mode of administration (i.e., injection) could
have led to different results. The metabolic response, however, indicates a substantial biological
effect. Vitamin B12 is involved in 2 biochemical reactions in humans [31]. In 1 of these, vitamin
B12 is required for the transfer of methyl groups, which includes remethylation of homocyste-
ine to methionine. Disruption of this pathway increases homocysteine and affects gene regula-
tion and DNA synthesis [31]. Vitamin B12 also acts as an enzymatic cofactor for
methylmalonyl-CoA mutase, an enzyme involved in the catabolism of fats and amino acids.
Disruption of the latter pathway explains the increased MMA observed in vitamin B12 defi-
ciency. Our study provides causal evidence that both of these metabolic pathways are affected
by mild vitamin B12 deficiency in children, and their functioning improves with supplementa-
tion. Thus, despite no effects on the clinical outcomes, children in this population could bene-
fit from increasing the vitamin B12 intake as indicated by their improved metabolic profile.
The period of supplementation in the present study might not have covered a critical win-
dow where adequate vitamin B12 status is crucial for optimal growth and neurodevelopment.
Thus, initiating supplementation sooner, such as before or during pregnancy or earlier in
infancy, could have yielded different results.
Restricting the participants to mildly stunted children increased the internal validity and
statistical power of our study at the expense of the external validity. In other words, our
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recruitment strategy reduced the generalizability of our results, which is a limitation. It should
be noted that enrolling all infants from the community would result in a larger proportion
with adequate vitamin B12 status and, consequently, more children who would not respond to
the intervention. A design ensuring higher external validity could accordingly attenuate a
potential effect and, at the same time, increase the variability, both contributing to reduced sta-
tistical power. Reduced statistical power increases the risk of false-negative results (type II
errors), which particularly question null findings such as here. In addition, our study was
designed to measure the effects of vitamin B12 supplementation on several outcomes across
several subgroups, which reduced the probability of overlooking relevant short-term clinical
outcomes.
An important assumption of our study was that the inclusion criteria ensured we targeted
those who would benefit from supplementation. It is possible, however, that these stunted chil-
dren would suffer from deficiencies of other growth-limiting nutrients. We believe this poten-
tial bias was accounted for by providing other vitamins and minerals, by treating common
infections, and by giving zinc for diarrhea.
In summary, our results show that in Nepalese infants, daily vitamin B12 supplementation
improves vitamin B12 status and the metabolic profile expressed by the composite 3cB12 indi-
cator. The metabolic response indicates that this population could benefit from vitamin B12
supplementation, but the clinical consequences of subclinical deficiency in early childhood
remain uncertain.
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